journal article·2021-03-24

Immunization with a Self-Assembled Nanoparticle Vaccine Elicits Potent Neutralizing Antibody Responses against EBV Infection

Yin-Feng Kang, Xiao Zhang, Xiao-Hui Yu, Qingbing Zheng, Zhe Liu, Jiang-Ping Li, Cong Sun, Xiang-Wei Kong, Qian-Ying Zhu, Hai-Wen Chen, Yang Huang, Miao Xu, Qian Zhong, Yi-Xin Zeng, Mu-Sheng Zeng

Nano Letters· Volume 21· Issue 6
Publisher page

Abstract

Epstein–Barr virus (EBV) infection is a global health concern infecting over 90% of the population. However, there is no currently available vaccine. EBV primarily infects B cells, where the major glycoprotein 350 (gp350) is the main target of neutralizing antibodies. Given the advancement of nanoparticle vaccines, we describe rationally designed vaccine modalities presenting 60 copies of gp350 on self-assembled nanoparticles in a repetitive array. In a mouse model, gp350s on lumazine synthase (LS) and I3-01 adjuvanted with MF59 or aluminum hydroxide (Alhydrogel) elicited over 65- to 133-fold higher neutralizing antibody titers than the corresponding gp350 monomer to EBV. Furthermore, immunization with gp350D123-LS and gp350D123-I3-01 vaccine induced a Th2-biased response. For the nonhuman primate model, gp350D123-LS in MF59 elicited higher titers of total IgG and neutralizing antibodies than the monomeric gp350D123. Overall, these results support gp350D123-based nanoparticle vaccine design as a promising vaccine candidate for potent protection against EBV infection.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Viral-associated cancers and disorders · Immune Cell Function and Interaction · Lymphoma Diagnosis and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou 510060, P. R. China

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, P. R. China

Guangdong Provincial Institution of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, P. R. China

National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Science, Xiamen University, Xiamen 361102, P. R. China

Funding

Ministry of Science and Technology of the People's Republic of China · China Postdoctoral Science Foundation · National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province · the Guangdong Province Key Research and Development program

References (45)

Show source-provided references
1. 10.1016/S1470-2045(12)70137-710.1016/S1470-2045(12)70137-7 ↗
2. 10.1016/S2214-109X(16)30143-710.1016/S2214-109X(16)30143-7 ↗
3. 10.1038/nrc.2016.9210.1038/nrc.2016.92 ↗
4. 10.1186/s40880-019-0357-910.1186/s40880-019-0357-9 ↗
5. 10.1002/cac2.1200610.1002/cac2.12006 ↗
6. 10.1186/s40880-019-0368-610.1186/s40880-019-0368-6 ↗
7. 10.1038/216810a010.1038/216810a0 ↗
8. 10.1086/52381310.1086/523813 ↗
9. 10.1016/j.vaccine.2013.04.07110.1016/j.vaccine.2013.04.071 ↗
10. 10.1016/j.cell.2015.07.04310.1016/j.cell.2015.07.043 ↗
11. 10.3389/fimmu.2018.0093210.3389/fimmu.2018.00932 ↗
12. 10.1016/j.immuni.2019.03.01010.1016/j.immuni.2019.03.010 ↗
13. 10.1073/pnas.81.14.451010.1073/pnas.81.14.4510 ↗
14. 10.1016/j.celrep.2013.01.02310.1016/j.celrep.2013.01.023 ↗
15. 10.1038/nm83010.1038/nm830 ↗
16. 10.1128/JVI.00445-0710.1128/JVI.00445-07 ↗
17. 10.1073/pnas.77.5.297910.1073/pnas.77.5.2979 ↗
18. 10.1016/j.vaccine.2013.04.07110.1016/j.vaccine.2013.04.071 ↗
19. 10.1186/s12967-015-0415-210.1186/s12967-015-0415-2 ↗
20. 10.1038/ncomms1204110.1038/ncomms12041 ↗
21. 10.1126/science.123415010.1126/science.1234150 ↗
22. 10.1126/science.aat912010.1126/science.aat9120 ↗
23. 10.1038/nature1801010.1038/nature18010 ↗
24. 10.1126/science.119908110.1126/science.1199081 ↗
25. 10.1038/ncomms1466310.1038/ncomms14663 ↗
26. Desgranges C. · Biomedicine · 1976 · 25 · 349
27. Desgranges C. · Biomedicine · 1979 · 30 · 102
28. 10.1016/j.celrep.2013.09.01210.1016/j.celrep.2013.09.012 ↗
29. 10.1038/nsmb116110.1038/nsmb1161 ↗
30. 10.1016/0022-1759(84)90093-010.1016/0022-1759(84)90093-0 ↗
31. 10.4049/jimmunol.167.10.575810.4049/jimmunol.167.10.5758 ↗
32. 10.1128/JVI.64.3.1348-1352.199010.1128/JVI.64.3.1348-1352.1990 ↗
33. 10.1126/science.171803510.1126/science.1718035 ↗
34. 10.1074/jbc.M70632420010.1074/jbc.M706324200 ↗
35. 10.1146/annurev.iy.07.040189.00104510.1146/annurev.iy.07.040189.001045 ↗
36. 10.3181/00379727-128-3306110.3181/00379727-128-33061 ↗
37. 10.1038/233559a010.1038/233559a0 ↗
38. Dunkel V. C. · J. Natl. Cancer Inst · 1972 · 49 · 435
39. 10.1038/238353a010.1038/238353a0 ↗
40. Renegar K. B. · J. Immunol · 1991 · 146 · 197210.4049/jimmunol.146.6.1972 ↗
41. 10.1046/j.1365-2567.1998.00441.x10.1046/j.1365-2567.1998.00441.x ↗
42. 10.1016/j.vaccine.2013.11.06910.1016/j.vaccine.2013.11.069 ↗
43. 10.4049/jimmunol.173.5.314810.4049/jimmunol.173.5.3148 ↗
44. 10.1038/nbt133210.1038/nbt1332 ↗
45. 10.1002/eji.20073798410.1002/eji.200737984 ↗